Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Opsens Inc T.OPS

OpSens Inc. is a medical device cardiology-focused company. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. The Company’s segments include Medical and Industrial. The Medical segment focuses on physiological measurements, such as Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR) in the coronary artery disease market and also supplies a range of miniature optical sensors to measure pressure and temperature to be used in a range of applications that can be integrated into other medical devices. The Industrial segment develops, manufactures and installs fiber optic sensing solutions for critical and demanding industrial applications. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and lesions access. It is approved for sale in the United States, European Union, Japan and Canada.


TSX:OPS - Post by User

<< Previous
Bullboard Posts
Next >>
Post by retiredcfon Sep 11, 2023 11:03am
190 Views
Post# 35629347

Morgan Stanley

Morgan Stanley

Morgan Stanley chief U.S. equity strategist Michael Wilson stays adamantly bearish and believes markets are beginning to show typical late cycle behaviour,

“We view this year as an extension of the late cycle period often experienced when the Fed is expected to pause or reverse its hawkish policy stance. As is typical in such periods, multiple expansion has moved ahead of where macro fundamentals dictate fair value to be, placing the burden on a growth reacceleration and/or incremental policy support that’s not already in the price in order to keep multiples elevated … Late cycle/more conservative factors are outperforming once again. Specifically, we note that high cash, low debt and low capex factors have performed well over the last month; long term growth and strong sales/earnings revisions factors are also working. Interestingly, despite the rate move higher since the local peak in equities in late July, growth has outpaced both value and cyclicals. Further, a broad set of early cycle winners have seen relative underperformance recently. In our view, this supports our preference for a late cycle playbook. Overweight Health Care...Health Care has underperformed the market year-to-date but is showing relative strength against other defensive pockets”

<< Previous
Bullboard Posts
Next >>